Prescription medication · Alpha-1 Blocker (BPH)
alfuzosin
Also sold as Uroxatral. This medicine treats the symptoms of benign prostatic hyperplasia (BPH), also known as an enlarged prostate.
Data updated 2026-05-15
- 2,222
- FDA reportsRarely reported
- 5
- InteractionsFew interactions
- $0.11
- Generic price (NADAC)
What the data shows
alfuzosin (Uroxatral) is a prescription Alpha-1 Blocker (BPH), among the least-reported drugs the FDA tracks (2,222 FDA reports), with 5 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
alfuzosin (Uroxatral) is a prescription Alpha-1 Blocker (BPH). This medicine treats the symptoms of benign prostatic hyperplasia (BPH), also known as an enlarged prostate.
Alfuzosin is a medicine that helps men with enlarged prostate glands. It relaxes the muscles in the prostate and bladder, making it easier to urinate.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Generic Price
$0.11/unit
Generic Available
Yes (5 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
NADAC price trail: ALFUZOSIN HCL ER 10 MG TABLET
Same CMS presentation as the headline generic unit price above (2 effective dates). Adjacent % compares consecutive NADAC releases for this description only, not a patient out-of-pocket quote. Latest step: -8.2% vs prior release.
| Effective | NADAC / unit | vs prior | NDCs |
|---|---|---|---|
| February 21, 2024 | $0.1150/EA | - | 3 |
| December 18, 2024 | $0.1056/EA | -8.2% | 12 |
What it does
This medicine treats the symptoms of benign prostatic hyperplasia (BPH), also known as an enlarged prostate.
Common side effects
Dizziness, Upper respiratory tract infection, Headache
Key warnings
Alfuzosin can cause your blood pressure to drop suddenly when you stand up, leading to dizziness or fainting.
The sections below are summarized in plain English from alfuzosin's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Alfuzosin belongs to a class of drugs called alpha-1 blockers. It works by relaxing the muscles in the prostate and bladder neck. This relaxation allows urine to flow more freely, relieving the symptoms of BPH.
Side Effects (from patient reports)
Based on 2,222 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for alfuzosin, by number of reports
- Dyspnoea
Dyspnoea
89 reports
- Drug Interaction
Drug Interaction
87 reports
- Fatigue
Fatigue
87 reports
- Acute Kidney Injury
Acute Kidney Injury
79 reports
- Dizziness
Dizziness
74 reports
- Hypotension
Hypotension
74 reports
- Diarrhoea
Diarrhoea
71 reports
- Asthenia
Asthenia
68 reports
- Fall
Fall
62 reports
- Confusional State
Confusional State
54 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for alfuzosin each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where alfuzosin sits
alfuzosin has more FDA adverse-event reports than 14% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is alfuzosin; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 2,222 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.
Total Reports
2,222
Reports Mentioning Death
212
9.5% of reports — not proof of cause
Hospitalization Reports
1,009
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 3 | DYSPNOEA | 89 |
| 4 | DRUG INTERACTION | 87 |
| 5 | FATIGUE | 87 |
| 6 | ACUTE KIDNEY INJURY | 79 |
| 7 | DIZZINESS | 74 |
| 8 | HYPOTENSION | 74 |
| 9 | DIARRHOEA | 71 |
| 10 | ASTHENIA | 68 |
| 11 | FALL | 62 |
| 12 | CONFUSIONAL STATE | 54 |
| 13 | DEATH | 53 |
| 14 | MALAISE | 48 |
| 15 | NAUSEA | 48 |
| 16 | HEADACHE | 47 |
| 17 | PNEUMONIA | 47 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Alfuzosin can cause your blood pressure to drop suddenly when you stand up, leading to dizziness or fainting. Be careful when standing up quickly, especially when you first start taking this medicine. If you have chest pain (angina), tell your doctor immediately. This medicine may also affect your heart rhythm. Tell your doctor if you have a history of heart problems.
Known Drug Interactions
7 DRUG INTERACTIONS Concomitant use of PDE5 inhibitors with alpha adrenergic antagonists, including alfuzosin hydrochloride extended-release tablets, can potentially cause symptomatic hypotension ( 5.4 , 7.4) 7.1 CYP3A4 Inhibitors Alfuzosin hydrochloride extended-release tablets are contraindicated for use with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, or ritonavir, since alfuzosin blood levels are increased [see Contraindications ( 4 ), Warnings and Precautions ( 5.4) and Clinical Pharmacology ( 12.3) ].
Mechanism: Ketoconazole blocks the enzyme that breaks down alfuzosin, which causes the amount of alfuzosin in your blood to rise to unsafe levels.
Other Agents Alpha 1-adrenoreceptor antagonist: alfuzosin ↑ alfuzosin Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as hypotension.
Mechanism: Darunavir prevents your body from getting rid of alfuzosin, which can cause the drug to reach high levels and lead to dangerously low blood pressure.
Table 2: Established and Other Potentially Significant Drug Interactions Drug Class Drugs within Class Effect on Concentration Clinical Comments Alpha 1- adrenoreceptor antagonist alfuzosin ↑ alfuzosin Co-administration contraindicated due to potential hypotension [see Contraindications (4) ] .
Mechanism: Nirmatrelvir/ritonavir causes alfuzosin to build up in your body by slowing its removal. This can lead to a dangerous drop in your blood pressure.
Table 1:Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Examples of Concomitant Drugs Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers Alfuzosin Silodosin Tamsulosin Not recommended during and 2 weeks after itraconazole treatment.
Mechanism: Itraconazole slows down the breakdown of alfuzosin in your body, which can lead to an unsafe buildup of the medication. This increases your risk of having a bad reaction to the alfuzosin.
Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, tamsulosin or alfuzosin.
Mechanism: Both of these medicines can relax your blood vessels, which may lead to a further drop in blood pressure when taken together.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
Can I take alfuzosin if I have liver problems?
Can I take alfuzosin with other medications?
What should I do if I feel dizzy after taking alfuzosin?
Can alfuzosin cure my enlarged prostate?
How long does it take for alfuzosin to start working?
Can I drink alcohol while taking alfuzosin?
What if I am having cataract surgery?
Can I take alfuzosin if I have kidney problems?
Is alfuzosin safe for children?
What does alfuzosin look like?
What are the common side effects of alfuzosin?
Does alfuzosin interact with other medications?
What drug class is alfuzosin?
What pregnancy or breastfeeding source fields are listed for alfuzosin?
Related Medications in Alpha-1 Blocker (BPH)
Other drugs grouped near alfuzosin - same-class peers and common alternatives.
bethanechol
Urecholine
Bethanechol helps you to urinate if you have trouble emptying your bladder.
Compare with alfuzosin →
darifenacin
Enablex
Darifenacin (Enablex) is a medicine that helps control an overactive bladder.
Compare with alfuzosin →
dutasteride
Avodart
Dutasteride and tamsulosin hydrochloride capsules contain two medicines to treat enlarged prostate in men.
Compare with alfuzosin →
dutasteride/tamsulosin
Jalyn
This medicine combines two drugs to treat enlarged prostate in men.
Compare with alfuzosin →
fesoterodine
Toviaz
Fesoterodine is a medicine that helps control an overactive bladder.
Compare with alfuzosin →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for alfuzosin: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 2,222.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 9.54%.
- repaglinide Δ 0.04 pts · 7,180 reports · Meglitinide 9.58%death share
- vigabatrin Δ 0.04 pts · 14,085 reports · Anticonvulsant (GABA Transaminase Inhibitor) 9.58%death share
- sitagliptin Δ 0.07 pts · 70,292 reports · DPP-4 Inhibitor 9.47%death share
- fosinopril Δ 0.09 pts · 4,213 reports · ACE Inhibitor 9.45%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on alfuzosin
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for alfuzosin
The FDA label for alfuzosin (sold under brand names such as Uroxatral) classifies it as a prescription-only medication in the Alpha-1 Blocker (BPH) class. This medicine treats the symptoms of benign prostatic hyperplasia (BPH), also known as an enlarged prostate. Official labeling lists 4 commonly reported side effects, including Dizziness, Upper respiratory tract infection, Headache.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 2,222 voluntary reports. The database also lists 5 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated major severity. NADAC pricing from CMS shows a generic unit cost of $0.11.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: April 2, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages